Aerpio Pharmaceuticals (OTCMKTS:ARPO) Releases Earnings Results, Beats Expectations By $0.01 EPS

Aerpio Pharmaceuticals (OTCMKTS:ARPO) posted its earnings results on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01, Fidelity Earnings reports.

Shares of OTCMKTS ARPO remained flat at $$0.54 during mid-day trading on Friday. 48,700 shares of the stock were exchanged, compared to its average volume of 255,318. The firm’s fifty day moving average is $0.59 and its 200-day moving average is $0.80. Aerpio Pharmaceuticals has a one year low of $0.45 and a one year high of $4.25.

ARPO has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research note on Wednesday, October 9th. HC Wainwright set a $1.00 target price on shares of Aerpio Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, October 21st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Aerpio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $3.25.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Earnings History for Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply